Venous thromboembolism (VTE) impacts thousands of patients with hereditary AT deficiency each year1

  • Hereditary AT deficiency (HATD) affects 1 in every 500 to 5000 individuals2-4
    • This range suggests that approximately 63,000 to 630,000 people in the United States (US) are affected5
  • More than 250,000 patients are hospitalized for VTE each year in the US6
    • Up to 7500 (3%) of these patients may have hereditary AT deficiency1

Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.


References

  1. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;43(3):249-290.
  2. Thrombate III® (antithrombin III [human]) Prescribing Information. Grifols.
  3. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol. 1994;45:321-324.
  4. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):1229-1239.
  5. US Census Bureau, Population Division. US and World Population Clocks—POPClocks. www.census.gov/main/www/popclock.html. Revised May 31, 2012. Accessed August 21, 2012.
  6. Lloyd-Jones D, Adams J, Brown TM, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.